Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240304 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
A Phase 2 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01240304 is a Phase 2 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 10 participants.
The verdict
NCT01240304, a Phase 2 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this phase II clinical trial study is to assess the resection rate among subjects who have been initially diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma. This will be done by providing preoperative treatment that will include alternating cycles of chemotherapy and radiotherapy treatment. In addition, this clinical trial will assess the safety of preoperative chemotherapy with radiation therapy for subjects with unresectable or borderline resectable adenocarcinoma of the pancreatic head, assess margin-negative resection rates, disease-free survival, assess overall survival rates, and determine patterns of local and distant recurrence.
Interventions
- DRUG Gemcitabine
- RADIATION Radiation therapy
- PROCEDURE pancreaticoduodenectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-11 |
| Est. Completion | 2019-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240304
The ClinicalTrials.gov registry entry for NCT01240304 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT01240304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240304 about?
NCT01240304 is a clinical study titled "A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas". The purpose of this phase II clinical trial study is to assess the resection rate among subjects who have been initially diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma. This will be done by providing preoperative treatment that will include alternating cycles of chemo...
What is the current status of trial NCT01240304?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-11. Estimated completion is 2019-10.
What interventions are being tested in trial NCT01240304?
The interventions under investigation include: Gemcitabine (DRUG), Radiation therapy (RADIATION), pancreaticoduodenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT01240304?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.